Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Paediatric first for Chagas disease

This article was originally published in Scrip

Executive Summary

The first ever paediatric formulation of benznidazole, the most common treatment for Chagas disease, should be available by the end of next year. Furthermore, through a partnership between Brazil's state owned Pharmaceutical Laboratory of Pernambuco (Lafepe) and the Drugs for Neglected Diseases initiative(DNDi), the drug will be distributed throughout countries where Chagas disease is endemic at cost-price. Lafepe will develop and produce the drug and do all the necessary paperwork for the drug to be approved while the initiative will help register the drug with government authorities, develop distribution strategies for endemic countries and assist in the Pan-American Health Organisation pre-qualification of the product. Children are currently being treated with fractions of tablets formulated for adults, which significantly increases the risk of errors that can affect the safety, efficiency and quality of the medicine as well as compliance. Chagas disease is endemic across central and South America, as well as Mexico.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts